Aga Khan University Clinical Trials Unit (CTU)

Experience

Phase 3 Coronavirus Vaccine in 2900 subjects. Site previously performed Phase 2a trial for NVGH Glycoconjugate Vaccine in 160 participants, Phase 4 for mOPV1 and bOPV1&3 oral polio vaccines in 800 participants, Phase 4 evaluation of Mucosal Immunity to Polioviruses Following Administration of bOPV and IVP in 1250 participants, Phase 4 evaluation of immunogenicity of Rotavirus Vaccines provided on different schedules and with/without breastfeeding in 1140 participants.

Co-PI previously performed trial 1 to evaluate malaria vaccine in 75 subjects and phase 4 of rotavirus vaccine in 1140 subjects"

Disease areas

• COVID-19
• Enteric diseases
• Malaria